What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Lung cancer, Internal medicine, Oncology, Surgery and Chemotherapy.
Frances A. Shepherd has included themes like Cancer, Cancer research and Carcinoma in her Lung cancer study.
Her studies deal with areas such as Stage, Gemcitabine, Cisplatin and Docetaxel as well as Oncology.
Her Surgery research incorporates elements of Gastroenterology, Placebo and Quality of life.
Her research integrates issues of Adjuvant and Regimen in her study of Chemotherapy.
Her biological study spans a wide range of topics, including Erlotinib Hydrochloride, Erlotinib, Proportional hazards model, Subgroup analysis and Adenocarcinoma.
Her most cited work include:
- Erlotinib in previously treated non-small-cell lung cancer. (4802 citations)
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy (2111 citations)
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (1917 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Internal medicine, Lung cancer, Oncology, Chemotherapy and Surgery.
The study of Internal medicine is intertwined with the study of Gastroenterology in a number of ways.
Her Lung cancer research is multidisciplinary, relying on both Cancer, Epidermal growth factor receptor, Adenocarcinoma, Cancer research and Carcinoma.
Frances A. Shepherd has researched Cancer research in several fields, including Lung and Immunology.
Her study looks at the relationship between Oncology and topics such as Docetaxel, which overlap with Pemetrexed.
Her work deals with themes such as Placebo and Gefitinib, which intersect with Erlotinib.
She most often published in these fields:
- Internal medicine (70.62%)
- Lung cancer (61.54%)
- Oncology (55.23%)
What were the highlights of her more recent work (between 2016-2021)?
- Internal medicine (70.62%)
- Oncology (55.23%)
- Lung cancer (61.54%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Internal medicine, Oncology, Lung cancer, Cancer research and Cancer.
Her study in the fields of Chemotherapy, Osimertinib, Cohort and T790M under the domain of Internal medicine overlaps with other disciplines such as In patient.
The various areas that Frances A. Shepherd examines in her Oncology study include Stage, Confidence interval and Durvalumab.
Her Lung cancer research is multidisciplinary, incorporating elements of Clinical trial, Incidence, Epidermal growth factor receptor, Carcinoma and Hazard ratio.
Frances A. Shepherd has included themes like Mutant, Gene, Immune checkpoint inhibitors, Lung and Adenocarcinoma in her Cancer research study.
Her Cancer research is multidisciplinary, incorporating perspectives in Physical therapy, DNA methylation and Somatic cell.
Between 2016 and 2021, her most popular works were:
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (1571 citations)
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. (563 citations)
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (272 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Her primary scientific interests are in Lung cancer, Internal medicine, Oncology, Osimertinib and Cancer.
Her Lung cancer research includes elements of Clinical trial, Incidence, Epidermal growth factor receptor, Carcinoma and Immunotherapy.
Her study on Internal medicine is mostly dedicated to connecting different topics, such as Surgery.
Her studies in Oncology integrate themes in fields like Tyrosine-kinase inhibitor and Docetaxel.
Her work carried out in the field of Osimertinib brings together such families of science as Disease progression, EGFR T790M and Interstitial lung disease.
Frances A. Shepherd interconnects Epistasis, Epistasis and functional genomics, Physical therapy and Single-nucleotide polymorphism in the investigation of issues within Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
